Patient P-02593

Synthetic patientMETA-24 · Day 172 · 65–74 · M · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Unstable

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 89 ME-01 recommended — Monitoring Escalation ME-01
Day 90 Patient accepted — Started ME-01 in the companion
Day 93 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

Toxicity+10
Treatment adherence-8
GI instability-7
Nutritional resilience+4
Inflammatory activity-2

What helped?

Monitoring Escalation ME-01Day 89
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- WearableSleep 5.2 h, below personal baseline
Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 58
- WearableHRV 26 ms, trending down
Autonomic recovery ↓40
- Wearable1,369 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 62

DNA

Fictional pharmacogenomic panel

CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.2 · butyrate capacity 43/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 34 ms
Sleep: 5.2 h
Steps: 1,044
Resting HR: 68 bpm

Daily log: GI score 56, nutritional resilience 35, adherence 37.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02253	49%	S14	NP-02	no change	41
P-02320	49%	S14	NP-02	improved	50
P-02594	49%	S20	—	—	45
P-02157	46%	S14	ME-01	improved	55
P-02363	46%	S14	GI-04	improved	49
P-02582	46%	S14	ME-01	improved	45
P-02014	44%	S14	GI-04	improved	48
P-02118	44%	S14	GI-04	improved	47
P-02505	44%	S14	NP-02	improved	45
P-02535	44%	S14	SC-12	improved	50
P-02574	44%	S14	ME-01	improved	45
P-02039	43%	S14	—	—	38